Get notified when PRLD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Insider Participation (new) — Entities affiliated with directors and 5% stockholders are purchasing a significant portion of the offering, concentrating ownership and signaling potential conflicts.
- Dilution (new) — New investors face immediate dilution of $2.54 per share, and the offering excludes 14.7M options and 19.5M pre-funded warrants that could further dilute.
- Insufficient Funding (new) — The company explicitly states that the offering proceeds will not be sufficient to fund product candidates through regulatory approval, requiring substantial additional capital.
Prelude Therapeutics prices $90M offering at $4.44/share; net proceeds $85.5M fund operations into Q2 2028
Filed April 21, 2026 · ~1 min read
Key Changes
-
high
Prelude is selling 18,018,014 shares at $4.44 and 2,252,252 pre-funded warrants; gross proceeds about $90M before discounts.
The Offering verify on EDGAR → -
high
Company estimates net proceeds of $85.5M after underwriting discounts and expenses; will fund operations into Q2 2028.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $2.54 per share ($2.59 if pre-funded warrants exercised).
Dilution verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (IMMR 10-Q) is open in full — no account needed.
Partner
Trade PRLD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify